You are here

Article Text

Article menu
Download PDFPDF
Letter
Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment
  1. S Nishida1,
  2. K Hagihara1,
  3. Y Shima1,
  4. M Kawai1,
  5. Y Kuwahara1,
  6. J Arimitsu1,
  7. T Hirano1,
  8. M Narazaki1,
  9. A Ogata1,
  10. K Yoshizaki2,
  11. I Kawase1,
  12. T Kishimoto3,
  13. T Tanaka1
  1. 1
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
  2. 2
    Centre for Advanced Science and Innovation, Osaka University, Osaka, Japan
  3. 3
    Laboratory of Immune Regulation, Osaka University Graduate School of Frontier Biosciences, Osaka, Japan
  1. Dr T Tanaka, Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2–2 Yamada-oka, Suita City, Osaka 565–0871, Japan; ttanak{at}imed3.med.osaka-u.ac.jp

https://doi.org/10.1136/ard.2008.099267

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases.1 Amyloid fibril deposition causes progressive deterioration in various organs.

    In October 2007, a 50-year-old woman was admitted to our hospital with severe diarrhoea and weight loss. She had had rheumatoid arthritis (RA) for 12 years. Despite vigorous treatment with prednisolone and disease-modifying anti-rheumatic drugs (DMARDs), including bucillamine, sulfasalazine, auranofin, leflunomide and methotrexate or tacrolimus, her disease remained active.

    In January 2007, treatment was started with biological drugs. Subcutaneous injection of 25 mg of etanercept twice weekly for 2 months and, subsequently, intravenous injection of 3 mg/kg infliximab for 5 months combined with 20 mg of prednisolone …

    View Full Text

    Footnotes

    • Funding: This study was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation.

    • Competing interests: TK holds a patent for tocilizumab. The other authors declare no competing interests.

    • Ethics approval: Approval from the ethics committee of Osaka University Hospital.